<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> are possible complications in patients treated for previous <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapeutic strategies in these type of disorders are still not well defined: <z:chebi fb="0" ids="2038">azacitidine</z:chebi> has been recently approved for the treatment of higher risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, but few data are published relating possible efficacy in therapy-related dysplastic disorders </plain></SENT>
<SENT sid="2" pm="."><plain>We reported here 4 patients treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> for therapy related <z:mpath ids='MPATH_589'>dysplasia</z:mpath> after chemotherapy for non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>